banner
 
bar

program

slides
bar
 
 

Optimizing Management of Primary and Familial Hypercholesterolemia

WebCAST

pre-program survey
We Invite You to Take a Moment and Complete This
Pre-Program Knowledge and Clinical Performance Survey.
Thank You

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period November 7, 2012 through November, 2014, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all five segments totaling 2.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form; and 4) print out your CME certificate.

Registration

Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

logoSupported by an educational grant from sanofi-aventis U.S. and Regeneron Pharmaceuticals

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Complete Conference Management and CMEducation Resources, LLC. Complete Conference Management is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Complete Conference Management designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of Complete Conference Management to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by Complete Conference Management are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

PAUL RIDKER, MD
Program Co-Chair
Eugene Braunwald Professor of Medicine
Director, Center for Cardiovascular Disease Prevention
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA

Research Grant: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation;
Amgen Inc
Consultant/Advisory Board: Merck & Co., Inc.; Isis Pharmaceuticals, Inc.; Vascular Biogenics Ltd.; Amylin
Pharmaceuticals, Inc.; Genzyme Corporation


JAMES M. McKENNEY, PharmD
Program Co-Chair
Professor Emeritus
Virginia Commonwealth University School of Medicine
President and Chief Executive Officer
National Clinical Research, Inc.
Richmond, VA

Nothing to disclose


MICHAEL H. DAVIDSON, MD,. FACC, FACP, FNLA

Director of Preventive Cardiology
The University of Chicago Pritzker School of Medicine
Clinical Professor
The University of Chicago Pritzker School of Medicine
Chicago, IL

Consultant/Advisory Board: Amgen, Merck. Roche, Sanofi-aventis
Stockholder: Omthera Pharmaceuticals



EVAN A. STEIN, MD, PhD
Voluntary Professor Pathology & Laboratory Medicine
University of Cincinnati
Director
Metabolic & Atherosclerosis Research Center
Cincinnati, OH

Speaker/Honoraria: Regeneron/Sanofi, Amgen, Genentech/Roche, BMS
Research Grants: Regeneron/Sanofi, Amgen, Genentech/Roche, BMS
Consultant/Advisory Board: Regeneron/Sanofi, Amgen, Genentech/Roche, BMS

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Understand the unmet need for residual CV risk reduction in patients with primary hyperlipidemia and FH who are not achieving optimal LDL target goals in the setting of optimal statin-based management.
  • Determine the optimal LDL-C target goals for patients with primary hyperlipidemia and HeFH, based on a number of criteria and consensus recommendations including risk categories and/or maximally attainable LDL-C reductions.
  • Understand and act upon the clinical implications of the underlying genetic mutations, including LDLR and APOB mutations, that underpin impaired LDL receptor function or LDL removal in patients with HeFH; and how these genetic disorders have provided a portal into the understanding of novel LDL targets of possible therapeutic significance.
  • Optimally employ currently available, statin-based treatment regimens to achieve LDL-C target goals for HeFH, and be able to act upon the indications and clinical triggers for more aggressive LDL-C lowering in high risk patients.
  • Understand the types and metabolic consequences associated with the genetic underpinnings of FH and hyperlipidemia, including causes that lead to impaired LDL receptor function and impaired LDL removal; LDLR mutations, APOB mutations that impair LDLR binding and PCSK9 gain of function mutations.

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2012 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.


bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC and Pharmatecture, LLC

 
6

 

Key Program Topics Include:

Abetalipoproteinemia
AEGR-733
Anacetrapib
Allele
Antisense Oligonucleaotide
apheresis
Apo B
Apo B-100
ASO
Atheroprotection
Atorvastatin

CETP
cholesterol
Dutch Lipid Clinic Network Diagnostic Criteria
Ezetimibe
Familial Hyperlipidemia
FH
HDL
Heterozygous
homozygous
Hypercholesterolemia
LDL



LDLR
Lomitapide
Lp(a)
mAb
MEDPED
Microsomal Triglyceride Transport Protein
Mipomersen
MTP
NCEP ATP III
PCSK9
PCSK9 Inhibitors
REGN727

niacin
REGN727/SAR236553
Rosuvastatin
SAR236553
Simon Broome
Statin
tendon xanthoma
UK NICE FH Guidelinesdulation
Neurosyphilis
NIMO
NMSS
Novantrone